Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Grundman

Showing results (31-40 of 78) with videos related to

Pageof 8
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2009
Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: what have we learned?Michael Grundman, Ronald C Petersen, David A Bennett, et al.
Archives of Neurology|January 11, 2007
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementiaCharles DeCarli, Giovanni B Frisoni, Christopher M Clark, et al.
Journal of Alzheimer'S Disease : JAD|September 14, 2020
Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart ReviewMyrlene Sanon Aigbogun, Martin Cloutier, Marjolaine Gauthier-Loiselle, et al.
Journal of Alzheimer'S Disease : JAD|April 3, 2026
Randomized, double-blind study of zervimesine in mild to moderate Alzheimer's diseaseEverard G B Vijverberg, Douglas W Scharre, Michael Woodward, et al.
JAMA|June 5, 2003
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trialPaul S Aisen, Kimberly A Schafer, Michael Grundman, et al.
Alzheimer'S & Dementia (New York, N. Y.)|February 7, 2019
A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's diseaseMichael Grundman, Roger Morgan, Jason D Lickliter, et al.
Journal of Molecular Neuroscience : MN|September 6, 2002
Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trialMichael Grundman, Drahomira Sencakova, Clifford R Jack, et al.
Alzheimer'S Research & Therapy|January 25, 2024
A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's diseaseChristopher H van Dyck, Adam P Mecca, Ryan S O'Dell, et al.
The New England Journal of Medicine|April 15, 2005
Vitamin E and donepezil for the treatment of mild cognitive impairmentRonald C Petersen, Ronald G Thomas, Michael Grundman, et al.
Journal of Alzheimer'S Disease : JAD|December 8, 2015
Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's DiseaseGerald Novak, Nick Fox, Shona Clegg, et al.
Pageof 8

Showing results (31-40 of 78) with videos related to

Sort By:
Pageof 8
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2009
Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: what have we learned?Michael Grundman, Ronald C Petersen, David A Bennett, et al.
Archives of Neurology|January 11, 2007
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementiaCharles DeCarli, Giovanni B Frisoni, Christopher M Clark, et al.
Journal of Alzheimer'S Disease : JAD|September 14, 2020
Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart ReviewMyrlene Sanon Aigbogun, Martin Cloutier, Marjolaine Gauthier-Loiselle, et al.
Journal of Alzheimer'S Disease : JAD|April 3, 2026
Randomized, double-blind study of zervimesine in mild to moderate Alzheimer's diseaseEverard G B Vijverberg, Douglas W Scharre, Michael Woodward, et al.
JAMA|June 5, 2003
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trialPaul S Aisen, Kimberly A Schafer, Michael Grundman, et al.
Alzheimer'S & Dementia (New York, N. Y.)|February 7, 2019
A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's diseaseMichael Grundman, Roger Morgan, Jason D Lickliter, et al.
Journal of Molecular Neuroscience : MN|September 6, 2002
Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trialMichael Grundman, Drahomira Sencakova, Clifford R Jack, et al.
Alzheimer'S Research & Therapy|January 25, 2024
A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's diseaseChristopher H van Dyck, Adam P Mecca, Ryan S O'Dell, et al.
The New England Journal of Medicine|April 15, 2005
Vitamin E and donepezil for the treatment of mild cognitive impairmentRonald C Petersen, Ronald G Thomas, Michael Grundman, et al.
Journal of Alzheimer'S Disease : JAD|December 8, 2015
Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's DiseaseGerald Novak, Nick Fox, Shona Clegg, et al.
Pageof 8